



Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories



Brian J. Lopresti^{a,*}, Elizabeth M. Campbell^a, Zheming Yu^a, Stewart J. Anderson^b, Ann D. Cohen^c, Davneet S. Minhas^a, Beth E. Snitz^d, Sarah K. Royse^a, Carl R. Becker^a, Howard J. Aizenstein^c, Chester A. Mathis^a, Oscar L. Lopez^d, William E. Klunk^c, Dana L. Tudorascu^{b,c}

^a Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

^b Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA

^c Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

^d Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

ARTICLE INFO

Article history:

Received 15 October 2019

Received in revised form 21 May 2020

Accepted 23 May 2020

Available online 31 May 2020

Keywords:

Alzheimer's disease

Apolipoprotein-E

Positron emission tomography (PET)

Amyloid

Genetics

ABSTRACT

To characterize the influence of apolipoprotein-E (APOE) genotype on cerebral A β load and longitudinal A β trajectories, [¹¹C]Pittsburgh compound-B (PiB) positron emission tomography (PET) imaging was used to assess amyloid load in a clinically heterogeneous cohort of 428 elderly participants with known APOE genotype. Serial [¹¹C]PiB data and a repeated measures model were used to model amyloid trajectories in a subset of 235 participants classified on the basis of APOE genotype. We found that APOE- ϵ 4 was associated with increased A β burden and an earlier age of onset of A β positivity, whereas APOE- ϵ 2 appeared to have modest protective effects against A β . APOE class did not predict rates of A β accumulation. The present study suggests that APOE modifies Alzheimer's disease risk through a direct influence on amyloidogenic processes, which manifests as an earlier age of onset of A β positivity, although it is likely that other genetic, environmental, and lifestyle factors are important.

© 2020 Elsevier Inc. All rights reserved.

1. Introduction

An evolving view of late-onset Alzheimer's disease (LOAD) is that it is a complex and multifactorial disease in which genetic, environmental, and lifestyle factors modulate risk, age of onset, and disease progression (Bertram et al., 2007; Borenstein et al., 2006; Gatz et al., 2006). Evidence suggests that LOAD is driven by impairments in A β clearance rather than overproduction (Mawuenyega et al., 2010), although it is not well understood how LOAD risk factors conspire to modify disease pathophysiology and/or lower the threshold for detection of disease symptoms.

Three major polymorphic alleles of the APOE gene (ϵ 2, ϵ 3, ϵ 4) give rise to 3 apolipoprotein-E (apoE) isoforms (Rall et al., 1982; Roda et al., 2019). Much evidence suggests functional roles for apoE in regulating A β aggregation and clearance, and that these

functions are affected by the APOE genotype/apoE isoform. The presence of one or more ϵ 4 alleles of the APOE gene is associated with an increased risk of LOAD and an earlier age of onset in a gene dose-dependent manner (Bekris et al., 2011; Bird, 2008; Corder et al., 1993; Farrer et al., 1997; Saunders et al., 1993; Tang et al., 1996), whereas the APOE- ϵ 2 allele may have protective effects (Morris et al., 1995; Nagy et al., 1995; Wilson et al., 2002). Previous studies have examined the relationship between APOE genotype and the AD-related phenotype of cerebral A β deposition in positron emission tomography (PET) imaging studies. In general, these studies show that APOE- ϵ 4 is associated with increased cerebral A β load (Jansen et al., 2015; Mecca et al., 2018; Morris et al., 2010; Resnick et al., 2015; Wirth et al., 2014; Yan et al., 2018) and an accelerated rate of A β deposition (Grimmer et al., 2010; Villemagne et al., 2011), whereas APOE- ϵ 2 appears to protect against A β accumulation (Kim et al., 2017; Morris et al., 2010).

The present study seeks to provide further support for the concept of genetic modulation of amyloidogenic processes by replicating observed associations between APOE genotype and brain A β burden in a cross-sectional cohort ($n = 428$) and to model the influence of APOE genotype on amyloid trajectories in a

Study funding: National Institute of Aging grants AG025204, AG005133, and AG025516.

* Corresponding author at: B-938 PUH, Department of Radiology, 200 Lothrop Street, Pittsburgh, PA 15213, USA. Tel.: +1 412 647 1155; fax: +1 412 647 0700.

E-mail address: BrianL@pitt.edu (B.J. Lopresti).

subcohort (n = 235) with serial [^{11}C]Pittsburgh compound-B (PiB) assessments.

2. Methods

2.1. Study participants and study design

Potential study participants (n = 432) were identified retrospectively from a multistudy cohort with [^{11}C]PiB PET image data, cognitive assessments, and APOE genotyping. Subjects comprising this multistudy cohort were drawn from 14 different studies, although several ongoing studies of normal aging were the largest contributors of longitudinal data (Aizenstein et al., 2008; Butters et al., 2008; Lopez et al., 2018; Mathis et al., 2013; Nadkarni et al., 2019; Tudorascu et al., 2019). [^{11}C]PiB data were acquired over a 14-year period beginning in 2003.

Comprehensive multidomain neuropsychological assessment was completed with all participants as previously described (Mathis et al., 2013; Snitz et al., 2015). Only subjects with consensus diagnoses of cognitively normal (CN), mild cognitive impairment (MCI) (Albert et al., 2011), probable AD (McKhann et al., 2011), and dementia of unknown origin (DUO) were included. A DUO diagnosis applies to subjects with atypical dementia who fell into any of the following categories (Wolk et al., 2012): (1) patients with possible AD who received this diagnosis because of an atypical presentation, usually reflecting nonmemory cognitive symptoms or behavioral issues more prominent than typical AD; (2) patients with posterior cortical atrophy syndrome; (3) patients with primary progressive aphasia; and (4) patients in whom no diagnosis could be determined. Like MCI, DUO subjects are heterogeneous in terms of [^{11}C]PiB retention characteristics with standardized uptake value ratio (SUVR) values that range from control-like to AD-like (Wolk et al., 2012). It is believed that DUO subjects as a group are characterized by a spectrum of brain pathologies, often mixed or overlapping, where A β is a copathology in approximately one-third to one-half of cases.

Demographic information, clinical diagnoses, and baseline global [^{11}C]PiB retention indices for the full cohort are presented in Table 1. Serial [^{11}C]PiB data were available in a subcohort of 235 participants (Table 2). For cross-sectional analyses, only the baseline [^{11}C]PiB scans were used, whereas all available [^{11}C]PiB scans were used to model longitudinal trajectories. To examine the potential effects of selection bias, where MCI and AD subjects carry elevated genetic risk for APOE- ϵ 4 positivity, we performed parallel analyses in subcohorts of CN (control) subjects. Demographic

information is presented in Supplemental Table S1 for cross-sectional (n = 246) and Supplemental Table S2 (n = 173) for longitudinal control subjects.

APOE genotyping was performed on DNA extracts from blood as previously described (Kamboh et al., 1995). Participants were divided into 3 APOE classes: APOE- ϵ 2 carriers (APOE- ϵ 2+), APOE- ϵ 3 ϵ 3, and APOE- ϵ 4 carriers (APOE- ϵ 4+). Four participants having an APOE- ϵ 2 ϵ 4 genotype were excluded as they could not be unambiguously assigned to one APOE genotype class.

2.2. Standard protocol approvals, registrations, and patient consents

All participants or their proxies provided written consent, and all studies were performed with approval of the Institutional Review Board of the University of Pittsburgh.

2.3. Data acquisition

2.3.1. Magnetic resonance imaging

T1-weighted magnetic resonance (MR) images were acquired on one of 2 MR imaging systems: MR images acquired in 2009 and earlier (49%) were acquired on a 1.5 T GE Signa scanner, whereas later scans (51%) were acquired on a 3.0 T Siemens Magnetom Trio. Participants scanned on the 1.5 T GE Signa scanner were positioned in a standard head coil and a brief scout T1-weighted image was obtained. A volumetric spoiled gradient recalled sequence with parameters optimized for contrast among gray matter, white matter, and CSF were acquired in the coronal plane (TE/TR = 5/25, flip angle = 40°, NEX = 1, slice thickness = 1.5 mm/0 mm interslice). MR images acquired on the 3T Siemens Magnetom Trio used a magnetization-prepared rapid acquisition gradient-echo sequence (TI/TE/TR = 900/2.98/2300 ms, flip angle = 9°, slice thickness = 1.2 mm, matrix size = 160 × 240 × 256).

2.3.2. Positron emission tomography imaging

PET emission data were acquired on one of 2 Siemens ECAT HR+ PET scanners as previously described (Mathis et al., 2013). Briefly, participants were positioned in the scanner approximately 35 minutes after [^{11}C]PiB injection. A 10-minute transmission scan was acquired using rotating $^{68}\text{Ge}/^{68}\text{Ga}$ rod sources to correct for photon attenuation, followed by a 20-minute emission scan (4 × 5-minute frames) beginning 50 minutes after [^{11}C]PiB injection (15 mCi). PET emission data were reconstructed using filtered back-projection (direct inverse Fourier transform) into a 128 × 128 × 63 matrix

Table 1
Demographics and clinical characteristics for cross-sectional cohort (n=428) by APOE genotype class

Characteristic	APOE- ϵ 3 ϵ 3	APOE- ϵ 2+	APOE- ϵ 4+	Test Statistic (df), p-value
n	241	43	144	
Age at the baseline, y, mean (SD)	75.60 (9.81)	75.23 (10.28)	71.19 (9.87)	F: 9.31 (2), p = 0.0001
Education, y, mean (SD)	14.99 (2.71)	15.33 (2.82)	15.72 (3.13)	F: 2.88 (2), p = 0.058
MMSE score, median (IQR)	28 (27–29)	28 (27–29)	27 (23–29)	KW: 16.9 (2), p = 0.0002
Female sex, No. (%)	131 (54.13)	22 (52.38)	75 (52.08)	χ^2 : 0.27 (2), p = 0.873
Nonwhite race/ethnicity, No. (%)	14 (5.81)	4 (9.3)	13 (9.03)	Fisher's Exact: p = 0.371
Clinical Dx, No. (%)				χ^2 : 57.83 (6), p < 0.0001
Control	166 (67.5)	27 (11.0)	53 (21.5)	
MCI	47 (47.0)	13 (13.0)	40 (40.0)	
AD	17 (27.9)	1 (1.6)	43 (70.5)	
DUO	11 (52.4)	2 (9.5)	8 (38.1)	
Positive PiB status, No. (%)	80 (33.2)	8 (18.6)	93 (64.58)	χ^2 : 47.4 (2), p < 0.0001
Baseline [^{11}C]PiB SUVR, mean (SD)	1.54 (0.44)	1.36 (0.34)	1.84 (0.5)	F: 28.49 (2), p < 0.0001

Key: APOE, apolipoprotein-E; AD, Alzheimer's disease; DUO, dementia of unknown origin; IQR, interquartile range; KW, Kruskal-Wallis test; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; No., number; PiB, Pittsburgh compound-B; SD, standard deviation; SUVR, standardized uptake value ratio; y, years.

Table 2

Subject demographics and clinical characteristics for longitudinal subcohort (n = 235) by APOE genotype class

Characteristic	APOE-ε3ε3	APOE-ε2+	APOE-ε4+	Test Statistic (df), p-value
n	142	28	65	
Age at the baseline, y, mean (SD)	78.9 (8.92)	75.6 (10.2)	73.5 (9.23)	F: 7.98 (2), <i>p</i> = 0.00045
Education, y, mean (SD)	15.1 (2.66)	15.8 (2.80)	16.1 (3.19)	F: 2.84 (2), <i>p</i> = 0.0602
MMSE score, median (IQR)	29 (27–29)	28 (27–29)	28 (26–29)	KW: 4.00 (2), <i>p</i> = 0.14
Female sex, No.(%)	74 (52.11)	11 (39.29)	28 (43.08)	χ^2 : 2.44 (2), <i>p</i> = 0.29
Nonwhite race/ethnicity, No.(%)	10 (7.04)	3 (10.71)	6 (9.23)	Fisher's Exact: <i>p</i> = 0.68
Follow-up period, y, mean (SD)	4.48 (2.34)	4.03 (2.40)	3.39 (1.80)	F: 5.49 (2), <i>p</i> = 0.00468
Number of visits, mean (SD)	3.23 (0.97)	3.25 (1.4)	2.91 (0.84)	F: 2.45 (2), <i>p</i> = 0.0889
Clinical Dx., No. (%)				Fisher's Exact: <i>p</i> << 0.001
Control	119 (68.8)	19 (11.0)	35 (20.2)	
MCI	21 (44.7)	9 (19.1)	17 (36.2)	
AD	2 (14.3)	0 (0.0)	12 (85.7)	
DUO	0 (0.0)	0 (0.0)	1 (100.0)	
Globally PiB positive, No. (%)	52 (36.62)	4 (14.29)	44 (67.69)	χ^2 : 28.00 (2), <i>p</i> << 0.001
Baseline [¹¹ C]PiB SUVR, mean(SD)	1.56 (0.40)	1.33 (0.35)	1.86 (0.47)	F: 19.03 (2), <i>p</i> << 0.001

Key: APOE, apolipoprotein-E; AD, Alzheimer's disease; DUO, dementia of unknown origin; IQR, interquartile range; KW, Kruskal-Wallis test; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; No., number; PiB, Pittsburgh compound-B; SD, standard deviation; SUVR, standardized uptake value ratio; y, years.

with voxel sizes of $2.06 \times 2.06 \times 2.43 \text{ mm}^3$. Images were filtered with a 3 mm Hann window.

2.4. Data processing

MRI and [¹¹C]PiB PET images were processed as previously described (Rosario et al., 2011). Briefly, dynamic PET images were corrected for interframe motion and summed over 50–70 minutes (McNamee et al., 2009). MRI images were manually skull-stripped and reoriented with axial image planes parallel to the anterior-posterior commissure line. [¹¹C]PiB images were registered to skull-stripped MRIs using rigid body registration in AIR v3.0, and MRIs were resliced to PET resolution.

Manual region-of-interest (ROI) tracings were performed using ROITool software (Siemens Medical Systems, Knoxville, TN, USA) on skull-stripped MRIs. ROIs were defined bilaterally on 3 to 5 contiguous transverse image planes for anterior cingulate gyrus (ANC), anteroventral striatum (AVS), frontal cortex (FRC), parietal cortex (PAR), lateral temporal cortex (LTC), posterior cingulate/precuneus (PRC), and cerebellar gray matter (CER) and subsequently used to sample coregistered PET images as previously described (Cohen et al., 2009; Price et al., 2005). SUVRs were computed for all regions normalized to CER. A 6-region composite global [¹¹C]PiB SUVR index (GBL6) was also computed as previously described (Aizenstein et al., 2008).

To investigate the dilutional effects of atrophy on [¹¹C]PiB retention indices and Aβ trajectories, an MR-based 2-compartment (brain and CSF) partial volume correction (Meltzer et al., 1990) was applied to SUVR outcomes as previously described (Rosario et al., 2011). CSF-corrected [¹¹C]PiB SUVR values were compared with uncorrected SUVRs in all analyses.

[¹¹C]PiB positivity thresholds were determined using a sparse k-means clustering algorithm as previously described (Cohen et al., 2013). Subjects were adjudicated to be PiB-positive (PiB+) or negative (PiB-) at the baseline and follow-up examinations using the GBL6 composite index with a positivity threshold of SUVR = 1.51 (Cohen et al., 2013).

2.5. Statistical methods

Mean (standard deviation) is presented for normally distributed variables such as age, education, follow-up period, number of visits, and baseline [¹¹C]PiB SUVRs. Median (interquartile range) is provided for Mini-Mental State Examination (MMSE). Categorical

characteristics such as sex, ethnicity, diagnosis, and frequency of global [¹¹C]PiB positivity are summarized with frequencies and percentages (Tables 1 and 2). A one-way ANOVA was used for normally distributed variables having similar variances (age, education). A χ^2 test for categorical variables was used to test for differences in gender composition and frequency of [¹¹C]PiB positivity. Fisher's exact test was used to compare some categorical variables with few subjects in one or more cells (e.g., race, diagnostic classification). The Kruskal-Wallis rank test was used to test continuous variables such as MMSE score. The overall tests were followed up with post hoc pairwise comparisons using t-tests or the Wilcoxon signed rank test as appropriate. All pairwise comparisons were Bonferroni corrected.

After examining the relationship between [¹¹C]PiB SUVR and age by APOE class using basic data plots to characterize the type of association (e.g., linear, quadratic), our initial approach was to apply a repeated measures model with only the main effects of age and APOE genotype. Additional terms, quadratic terms, and their interactions with APOE were included to expand the basic model, which included age², age² × APOE interaction, diagnosis, and diagnosis × APOE interaction. We evaluated the Akaike Information Criterion, Bayesian Information Criterion, and t-value for each added term. Terms were added or dropped from the model based on this evaluation. The Kenward-Roger method (Kenward and Roger, 1997) was used for computing the degrees of freedom.

The final model included fixed factors of APOE genotype, age (time-dependent predictor), age², and their interactions to test the associations between APOE genotype and age over time, and to determine the age at which Aβ trajectories crossed the PiB positivity threshold (GBL6 SUVR > 1.51). The model included a random intercept and linear term to account for within-subject correlation. The following repeated measures model was fit for global [¹¹C]PiB SUVR (*y*) for subject *i* and observation *j*:

$$y_{ij} = \beta_0 + \beta_1 APOE4_i + \beta_2 APOE2_i + \beta_3 Age_{ij} + \beta_4 Age_{ij} \times APOE4_i + \beta_5 Age_{ij} \times APOE2_i + \beta_6 Age_{ij}^2 + \beta_7 Age_{ij}^2 \times APOE4_i + \beta_8 Age_{ij}^2 \times APOE2_i + v_{0i} + v_{1i} Age_{ij} + \epsilon_{ij}$$

where:

- (1) β_0 represents the average [¹¹C]PiB GBL6 SUVR value for the reference group (ε3ε3) at the baseline (intercept);

- (2) $APOE_i$ is a dummy variable for the APOE group factor for subject i , with 2 levels (APOE2 for the $\epsilon 2$ allele and APOE4 for the $\epsilon 4$ allele, while the $\epsilon 3$ allele is the reference category);
- (3) Age_{ij} represents age at serial observation j for subject i , fitted as continuous;
- (4) v_{0i} is the subject-specific variation from average intercept effect, and v_{1i} is the subject-specific variation from the average slope with the following variance/covariance matrix:

$$\begin{bmatrix} v_{0i} \\ v_{1i} \end{bmatrix} = N \left\{ \begin{bmatrix} 0 \\ 0 \end{bmatrix}, \begin{bmatrix} \sigma_{v_0}^2 & \sigma_{v_0 v_1} \\ \sigma_{v_0 v_1} & \sigma_{v_1}^2 \end{bmatrix} \right\} \text{ and } \epsilon_{ij} \sim N(0, \sigma_e^2)$$

is the random error term at the j th observation for subject i .

To determine the A β trajectories for the 3 APOE genotype classes, estimates of fit parameters (β_0 – β_5) were substituted into the model equation aforementioned and solved over an age range of 45–95 years as previously described (Tudorascu et al., 2019). The age of onset was determined by solving this equation for the age at which each trajectory crossed the global [^{11}C]PiB positivity threshold of SUVR = 1.51.

We also computed annualized changes in PiB retention (SUVR/year) for all longitudinal subjects over the longest follow-up interval. Incident [^{11}C]PiB positivity was defined as a change in [^{11}C]PiB status from negative to positive between baseline and terminal examinations.

SAS 9.4 (SAS institute, Cary, NC, USA) and R 3.4.2 (GNU General Public License), were used for statistical analyses.

3. Results

3.1. Cross-sectional analyses

Of the 428 participating subjects, 43 (10.0%) were classified as APOE- $\epsilon 2+$, all of whom expressed the APOE- $\epsilon 2\epsilon 3$ genotype. The APOE- $\epsilon 3\epsilon 3$ genotype was the most abundant (241/428 subjects, 56.3%), whereas APOE- $\epsilon 4+$ subjects (144/428, 33.6%) were a mixture of $\epsilon 3\epsilon 4$ (111/428, 25.9%) and $\epsilon 4\epsilon 4$ (33/428, 7.7%) genotypes. APOE- $\epsilon 2$, - $\epsilon 3$, and - $\epsilon 4$ allele frequencies in the full cohort were 0.050, 0.743, and 0.207, respectively, which are comparable with those reported in American populations (Eichner et al., 1990; Singh et al., 2006). A notable difference in our sample is an increased APOE- $\epsilon 4$ allele frequency compared with the local population frequency (0.207 vs 0.122) (Eichner et al., 1990), although this finding is consistent with memory clinic settings (van der Flier et al., 2008). All APOE classes had similar ($p = 0.873$) and nearly equal proportions of males and females (Table 1). APOE- $\epsilon 4+$ subjects were younger at the baseline than either APOE- $\epsilon 2+$ ($p = 0.0085$) or $\epsilon 3\epsilon 3$ ($p = 0.000022$) subjects. APOE- $\epsilon 4+$ subjects showed greater impairment on the MMSE (median [interquartile range]: 27 [23–29] than either APOE- $\epsilon 2+$ (28 [27–29]; $p = 0.025$) or APOE- $\epsilon 3\epsilon 3$ (28 [27–29]; $p = 0.000059$) subjects despite being significantly younger (Table 1, Fig. 1A). We also found statistically significant differences ($p < 0.001$) in the distribution of diagnostic groups between APOE classes for both cross-sectional (Table 1) and longitudinal cohorts (Table 2). There




Fig. 1. Distribution of age, MMSE, and baseline [^{11}C]PiB retention. Box and whisker plots comparing the distribution of age, MMSE score, and baseline [^{11}C]PiB retention between 3 APOE genotype classes for (A) the full ($n = 428$) cohort and (B) the longitudinal subcohort ($n = 235$). The box represents the interquartile range (IQR), where the median is marked by a horizontal line. The upper and lower whiskers extend up to 1.5 IQR from either the first or third quartile. Outliers are defined as points that fall beyond of the range of the whiskers (>1.5 IQR) and are plotted individually. Multiple comparisons were used to test for significant differences between pairs of APOE groups. Abbreviations: APOE, apolipoprotein-E; MMSE, Mini-Mental State Examination.

were no differences in cognition between APOE- ϵ 2+ and APOE- ϵ 3 ϵ 3 subjects ($p = 0.54$).

Non-CSF-corrected GBL6 [^{11}C]PiB SUVR was increased in APOE- ϵ 4+ subjects (1.84 ± 0.5) compared with either APOE- ϵ 2+ (1.36 ± 0.34 ; $p < 0.0001$) or APOE- ϵ 3 ϵ 3 (1.54 ± 0.44); $p < 0.0001$) subjects, whereas [^{11}C]PiB SUVR values in APOE- ϵ 2+ subjects was reduced compared with APOE- ϵ 3 ϵ 3 subjects ($p = 0.0079$) (Fig. 1A). These findings persisted after CSF correction (Supplemental Fig. E1).

In the control-only subcohort ($n = 246$), we observed significantly higher global [^{11}C]PiB retention in APOE- ϵ 4+ control subjects relative to both APOE- ϵ 3 ϵ 3 ($p = 0.026$) and APOE- ϵ 2+ ($p = 0.005$) controls (Table S1). There were no differences in education ($p > 0.673$) or MMSE ($p > 0.378$) between any APOE groups of control subjects ($p > 0.37$), although APOE- ϵ 4+ control subjects were significantly younger (~ 4.2 years) than APOE- ϵ 3 ϵ 3 control subjects (Table S1, $p = 0.013$).

3.2. Longitudinal analyses

The full longitudinal subcohort ($n = 235$) averaged approximately 3 visits over a span of ~ 4 years. The distribution of APOE genotypes in the longitudinal subcohort was similar to that in the full cohort (Table 2). Of the APOE- ϵ 4+ subjects, 11/65 (16.9%) were APOE- ϵ 4 homozygotes. In general, the longitudinal subcohort mirrored the full cohort in terms of the distribution of age, cognition, gender balance, ethnic composition, and baseline [^{11}C]PiB retention indices (Table 2), although not all significant findings in the full cohort reached statistical significance in the longitudinal subcohort (Fig. 1). Demographic information for the group of 173 control subjects with longitudinal is shown in Supplemental Table S2. Statistically significant differences in the age distribution, frequency of [^{11}C]PiB positivity and global [^{11}C]PiB retention indices between APOE classes were maintained in the controls-only group.

Individual trajectories of [^{11}C]PiB SUVR values are shown in Fig. 2. Among the longitudinal subjects, 95 (40.4%) were globally PiB-negative at the baseline and remained globally PiB-negative throughout the follow-up. A similar proportion of subjects (97/235, 41.3%) were globally PiB-positive at the baseline and remained PiB-positive. Of the remaining 43 subjects, 40 (17.0%) converted from PiB-negative to PiB-positive, whereas 3 subjects (1.3%) who were PiB-positive at the baseline reverted to PiB-negative (all were near the PiB-positivity cutoff). The proportion of PiB-positive

subjects at the baseline was highest for APOE- ϵ 4+ subjects (44/65; 67.7%) and lowest for APOE- ϵ 2+ subjects (4/28; 14.3%), whereas APOE- ϵ 3 ϵ 3 subjects were intermediate (52/142, 36.6%). For subjects that were PiB-negative at the baseline, conversion rates to PiB-positive (positive at latest examination) were identical for APOE- ϵ 4+ (7/21; 33.3%) and APOE- ϵ 3 ϵ 3 (30/90; 33.3%) subjects, whereas less than one-half as many APOE- ϵ 2+ subjects (3/24; 12.5%) converted.

Table 3 represents the estimates and their standard errors of the intercepts and slopes for each main effect and interaction term in the model. Also shown in Table 3 are t-statistics and degrees of freedom, p -values, and the 95% confidence intervals (CIs) for each estimate. The repeated measures model revealed significant interactions between age and APOE- ϵ 4+ genotype ($p = 0.0116$) as well as between age² and APOE- ϵ 4+ genotype ($p = 0.0097$) (Table 3). The estimate for the age² \times APOE- ϵ 4+ interaction is $\beta_7 = -0.0009$ with a 95% CI of $(-0.0016, -0.00023)$. The estimate $\beta_7 = -0.0009$ represents the mean difference in the slopes of [^{11}C]PiB SUVR and age² between APOE- ϵ 4+ and APOE- ϵ 3 ϵ 3 classes with all other model parameters fixed. Similarly, the estimate $\beta_8 = 0.0001$ represents the mean difference in the slopes of [^{11}C]PiB SUVR and age² between APOE- ϵ 2+ and APOE- ϵ 3 ϵ 3 classes.

A β trajectories showed distinct differences in the age of onset of global [^{11}C]PiB positivity for the full longitudinal cohort (Fig. 3). The trajectory for APOE- ϵ 3 ϵ 3 subjects had an average age of onset of global [^{11}C]PiB positivity of 77.9 years and a slope of 0.029 SUVR/year (95% CI: 0.023–0.036 SUVR/year) at the GBL6 positivity threshold (SUVR = 1.51). The APOE- ϵ 4+ trajectory showed an earlier age of onset of [^{11}C]PiB positivity of 61.1 years and a rate of accumulation of 0.043 SUVR/yr (95% CI: 0.022–0.063 SUVR/year). By contrast, APOE- ϵ 2+ showed a delayed age of onset of [^{11}C]PiB positivity of 82.0 years and a rate of accumulation of 0.035 SUVR/yr (95% CI: 0.018–0.052 SUVR/year). Similar longitudinal trajectories were observed in the control-only longitudinal subcohort ($n = 173$), although the age of onset of [^{11}C]PiB positivity in APOE- ϵ 4+ control subjects was found to be ~ 8 years later (69.3 years) than that observed for the full longitudinal cohort, whereas for both APOE- ϵ 2+ and APOE- ϵ 3 ϵ 3 control subjects, it was delayed only by ~ 2 years (Fig. 4). Compared with the full longitudinal cohort, rates of A β accumulation predicted by the model were unchanged for APOE- ϵ 3 ϵ 3 control subjects (0.029 SUVR/yr), whereas rates for APOE- ϵ 4+ control subjects were slightly less (0.033 SUVR/yr) and slightly greater (0.044 SUVR/yr) for APOE- ϵ 2+.




Fig. 2. Individual A β trajectories. Individual trajectories showing the change in global [^{11}C]PiB SUVR values by chronologic age are shown for longitudinal participants ($n = 235$) for 3 APOE genotype classes. For each participant, serial [^{11}C]PiB assessments are plotted as individual points where blue indicates A β positive values and red indicates A β negative values. The points are connected by line segments to match the positivity status of the earlier vertex. Abbreviations: APOE, apolipoprotein-E; SUVR, standardized uptake value ratio. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Table 3
Repeated measures analysis estimates

Effect	β (SE)	t (DF)	p-value	95% CI for β
Intercept	β_0 : 1.7924 (1.2353)	1.45 (157)	0.1488	(−0.6476, 4.2324)
APOE- ϵ 4+	β_1 : −4.7669 (2.1597)	−2.21 (198)	0.0284	(−9.0258, −0.5081)
APOE- ϵ 2+	β_2 : 0.3025 (2.7657)	0.11 (149)	0.9131	(−5.1624, 5.7674)
APOE- ϵ 3 ϵ 3	0	—	—	—
Age	β_3 : −0.0366 (0.0304)	−1.27 (174)	0.2299	(−0.09666, 0.02338)
Age \times APOE- ϵ 4+	β_4 : 0.1410 (0.0554)	2.54 (225)	0.0116	(0.03177, 0.2502)
Age \times APOE- ϵ 2+	β_5 : −0.0127 (0.0704)	−0.18 (167)	0.8575	(−0.1515, 0.1262)
Age \times APOE- ϵ 3 ϵ 3	0	—	—	—
Age ²	β_6 : 0.0004 (0.0002)	2.26 (187)	0.0250	(0.000054, 0.000796)
Age ² \times APOE- ϵ 4+	β_7 : −0.0009 (0.0004)	−2.61 (244)	0.0097	(−0.00164, −0.00023)
Age ² \times APOE- ϵ 2+	β_8 : 0.0001 (0.0005)	−0.2 (180)	0.8433	(−0.00080, 0.000978)
Age ² \times APOE- ϵ 3 ϵ 3	0	—	—	—

Key: APOE, apolipoprotein-E; DF, degrees of freedom.

p-values that are below the threshold of statistical significance ($p < 0.05$) are shown in bold. These identify statistically significant terms in the model equation.

Individual rates of A β accumulation, as indexed by annualized changes in [¹¹C]PiB SUVR, showed no significant effect of APOE genotype (Table 4) when compared with the full longitudinal subcohort ($p = 0.178$; $n = 235$), subjects PiB-positive at the baseline ($p = 0.551$; $n = 100$), or subjects PiB-negative at the baseline ($p = 0.340$; $n = 125$). Pairwise comparisons between APOE genotype classes also showed no significant differences in rates of amyloid accumulation, although small subsample sizes often limited comparisons to those between APOE- ϵ 3 ϵ 3 and APOE- ϵ 4+. Subjects PiB-negative at the baseline ($n = 125$) included a subgroup that converted to PiB-positive ($n = 40$) and represent cases of incident amyloid positivity. In this group, we found APOE- ϵ 4+ subjects to exhibit a faster rate of A β accumulation than APOE- ϵ 3 ϵ 3 subjects (0.09 ± 0.03 SUVR/year vs 0.06 ± 0.03 SUVR/year) which was significant ($p = 0.029$).

CSF correction of [¹¹C]PiB SUVR values had a modest impact on the shapes of A β trajectories. Using CSF corrected data, the repeated measures model identified the same main effects as uncorrected

data (APOE- ϵ 4, age²) and interactions (age \times APOE- ϵ 4 and age² \times APOE- ϵ 4) with similar levels of significance (data not shown). The CSF-corrected data identified age to be a significant main effect ($p = 0.02$), whereas uncorrected data did not ($p = 0.23$). Differences between CSF-corrected and uncorrected A β trajectories became more prominent with increasing age, although the shape and the relative differences between the 3 trajectories was preserved with CSF correction applied (Supplemental Fig. e-1).

4. Discussion

A main objective of this work was to demonstrate that APOE genotype is predictive of cerebral A β burden, the age of onset of A β positivity, and also the rate of A β accumulation. In our cohort of 428 subjects, we found the prevalence of A β positivity among APOE- ϵ 4+ to be approximately 65%, whereas the prevalence was 2-fold lower in APOE- ϵ 3 ϵ 3 subjects (33.2%), and nearly 4-fold lower in APOE- ϵ 2+ subjects (18.6%) (Table 1). These prevalence estimates are




Fig. 3. Modeling of A β trajectories. Global [¹¹C]PiB SUVR trajectories for the 3 APOE genotype classes based on a repeated measures model of serial data from a longitudinal subcohort ($n = 235$). The GBL6 positivity threshold of 1.51 SUVR is indicated by a black hatched line. Indicated also is the slope of a line tangent to each trajectory at the [¹¹C]PiB positivity threshold, which corresponds to the rate of A β accumulation at the threshold. Also shown is the age at which each trajectory crosses the positivity threshold. APOE- ϵ 4+ participants showed the earliest age of onset of A β positivity (61.1 y), whereas trajectories for APOE- ϵ 3 ϵ 3 and APOE- ϵ 2+ participants indicated a delay in the age of onset of A β positivity of 16.8 and 20.9 y, respectively. Abbreviations: APOE, apolipoprotein-E; SUVR, standardized uptake value ratio.




Fig. 4. Modeling of A β trajectories in control subjects. Global [^{11}C]PiB SUVR trajectories for the 3 APOE genotype classes based on a repeated measures model of serial data from a subgroup of control longitudinal subjects ($n = 173$). The GBL6 positivity threshold of 1.51 SUVR is indicated by a black hatched line. Indicated also is the slope of a line tangent to each trajectory at the [^{11}C]PiB positivity threshold, which corresponds to the rate of A β accumulation at the threshold. Also shown is the age at which each trajectory crosses the positivity threshold. APOE- $\epsilon 4+$ control subjects showed the earliest age of onset of A β positivity (69.3 y), whereas trajectories for APOE- $\epsilon 3\epsilon 3$ and APOE- $\epsilon 2+$ control subjects indicated a delay in the age of onset of A β positivity of 10.0 and 14.5 y, respectively. Abbreviations: APOE, apolipoprotein-E; SUVR, standardized uptake value ratio.

consistent with previous [^{11}C]PiB imaging studies (Bilgel et al., 2016; Jansen et al., 2015; Morris et al., 2010), including a recent meta-analysis (Jansen et al., 2015). We found that [^{11}C]PiB SUVR as a continuous measure was higher in APOE- $\epsilon 4+$ than either APOE- $\epsilon 3\epsilon 3$ or APOE- $\epsilon 2+$ groups ($p < 0.001$) and APOE- $\epsilon 2+$ was lower ($p = 0.0079$) than APOE- $\epsilon 3\epsilon 3$ (Fig. 1A). These findings are consistent with earlier studies in smaller cohorts, which in general show

increased A β burden in subjects with one or more APOE- $\epsilon 4$ alleles (Mecca et al., 2018; Wirth et al., 2014; Zwan et al., 2016), and also with postmortem neuropathological studies relating plaque burden and APOE genotype (Schmechel et al., 1993).

Acknowledging that APOE- $\epsilon 4$ is associated with both an increased prevalence of A β positivity and increased A β burden for elderly subjects of a given age, a logical question to investigate is

Table 4
Annualized changes in [^{11}C]PiB retention measures by APOE genotype class

Comparison	APOE- $\epsilon 3\epsilon 3$	APOE- $\epsilon 2+$	APOE- $\epsilon 4+$	Test Statistic (df), p-value
All Participants				
n	142	28	65	
Change (SUVR/yr), mean (SD)	0.03 (0.05)	0.04 (0.06)	0.05 (0.07)	F: 1.74(2), $p = 0.178^a$
$\epsilon 3\epsilon 3$ vs $\epsilon 2+$	0.03 (0.05)	0.04 (0.06)		$p = 0.481^b$
$\epsilon 3\epsilon 3$ vs $\epsilon 4+$	0.03 (0.05)		0.05 (0.07)	$p = 0.103^b$
$\epsilon 2+$ vs $\epsilon 4+$		0.04 (0.06)	0.05 (0.07)	$p = 0.574^b$
Participants PiB+ at the baseline				
n	52	4	44	
Change (SUVR/yr), mean (SD)	0.05 (0.07)	0.11 (0.09)	0.05 (0.08)	
Change (SUVR/yr), median (IQR)	0.06 (0.01–0.10)	0.08 (0.04–0.18)	0.06 (0.0–0.10)	KW: 1.19 (2), $p = 0.551^c$
$\epsilon 3\epsilon 3$ vs $\epsilon 4+$	0.06 (0.01–0.10)		0.06 (0.0–0.10)	$p = 0.936^d$
Participants PiB- at the baseline				
n	90	24	21	
Change (SUVR/yr), mean (SD)	0.02 (0.04)	0.03 (0.04)	0.04 (0.06)	F: 1.0 (2), $p = 0.369^a$
Change (SUVR/yr), median (IQR)	0.02 (0.0–0.05)	0.02 (0.0–0.06)	0.04 (0.0–0.08)	
$\epsilon 3\epsilon 3$ vs $\epsilon 4+$	0.02 (0.04)		0.04 (0.06)	$p = 0.340^e$
Incident PiB+ participants				
n	30	3	7	
Change (SUVR/yr), mean (SD)	0.06 (0.03)	0.09 (0.03)	0.09 (0.03)	
Change (SUVR/yr), median (IQR)	0.06 (0.04–0.08)	0.10 (0.05–0.11)	0.09 (0.06–0.12)	KW: 6.24(2), $p = 0.044^c$
$\epsilon 3\epsilon 3$ vs $\epsilon 4+$	0.06 (0.04–0.08)		0.09 (0.06–0.12)	$p = 0.029^d$

Key: APOE, apolipoprotein-E; IQR, interquartile, range; SUVR, standardized uptake value ratio.

^a p-value from one-way ANOVA.

^b p-value from paired t -test.

^c p-value from Kruskal-Wallis test.

^d p-value from nonparametric Wilcoxon test.

^e p-value from independent 2-sample t -test.

whether the increased A β burden is due to an earlier age of onset of amyloidogenic processes, an accelerated rate of A β accumulation, or both. The clinical onset of symptoms in LOAD is variable, even in subjects who are homozygous for APOE- ϵ 4 (Blackner et al., 1997; Durmaz et al., 2019; Jack et al., 2015; Sando et al., 2008). It is not known to what extent variability in the clinical age of onset of dementia parallels the age of onset of A β positivity, although evidence suggests that the clinical age of onset is influenced by a complex interaction of factors including comorbidities (i.e., cerebrovascular disease, diabetes), cognitive resilience factors, and likely other genetic and lifestyle factors.

Although there are few reports of longitudinal [^{11}C]PiB imaging studies designed to explore the association between APOE genotype and age of onset of A β positivity, the available data consistently show an earlier age of onset in APOE- ϵ 4+ subjects (Bilgel et al., 2016; Fleisher et al., 2013; Jansen et al., 2015; Mishra et al., 2018). Our study is consistent with these observations, where we found the age of onset of global [^{11}C]PiB positivity to be 61.1 years in APOE- ϵ 4+ subjects, which precedes APOE- ϵ 3 ϵ 3 subjects by ~16 years (Fig. 3). We found this association to be evident, albeit attenuated, in a subcohort of subjects with normal cognition with an age of onset of 69.3 years (Fig. 4), suggesting that the finding is not solely driven by those with impaired cognition at study entry. The trajectory model based on the full study cohort (Fig. 3) suggests that the inclusion of cognitively impaired subjects may bias the results toward an earlier age of onset of A β positivity. However, the model that includes only CN subjects (Fig. 4) is likely biased in the direction of a later age of onset as certainly some degree of cognitive impairment is expected in a group of subjects aged 75 years and older, of whom 20% are APOE- ϵ 4+ (Table S2). Indeed, recent population studies suggest that at least 30% of APOE- ϵ 4+ subjects aged 75 years and older meet the criteria for MCI or dementia, which can be higher or lower based on the cohort or APOE- ϵ 4 gene dose (Bonham et al., 2016; Qian et al., 2017). It should be noted that, while some studies have suggested [^{11}C]PiB positivity cutoffs such as those used in this study are too high (Villeneuve et al., 2015), Fig. 3 suggests that similar or perhaps exaggerated findings would have resulted from the application of lower cutoff values.

The question of if and to what extent APOE- ϵ 4 positivity influences the rate of A β accumulation is less clear. Some longitudinal A β imaging studies have suggested that APOE- ϵ 4 positivity is associated with an accelerated rate of A β accumulation (Grimmer et al., 2010; Mishra et al., 2018; Villemagne et al., 2011), whereas others have failed to show such an association (Jack et al., 2013; Resnick et al., 2015). Still other studies suggest a more complex association where age and/or disease state potentially modify the relationship between APOE- ϵ 4 and the rate of A β accumulation (Lim et al., 2017; Mishra et al., 2018). Indeed, for a sigmoidal biomarker trajectory like those suggested by Jack and Holtzman for A β (Jack and Holtzman, 2013), the transition from normal to abnormal biomarker status must be accompanied by an increase in the rate of change in the biomarker from zero during the antecedent normal period to some nonzero abnormal biomarker state. The observation of increased rates of A β accumulation during early disease phases would therefore be consistent with a sigmoidal biomarker trajectory. Once the biomarker reaches an abnormal value, the rate of biomarker change may remain constant or, as some studies suggest (Jack et al., 2013), reach a plateau at a more advanced age.

In the present study, longitudinal [^{11}C]PiB SUVR change measures (SUVR/year) determined for individual subjects (Table 4) did not show any effects of APOE genotype on the rate of A β accumulation that reached the level of significance, except for the subgroup of incident [^{11}C]PiB-positive cases ($n = 40$) where APOE- ϵ 4 positivity was associated with a higher rate of A β accumulation than

noncarriers ($p = 0.029$, Table 4). Although significant, this result must be interpreted with caution because of the small number of APOE- ϵ 4+ incident PiB-positive subjects ($n = 7$).

Our A β trajectory models were also used to assess rates of A β accumulation by calculating the slope of the trajectory at the global [^{11}C]PiB positivity threshold. Trajectory models showed strong agreement with individual change measures of [^{11}C]PiB retention (Table 4), predicting rates of A β accumulation in APOE- ϵ 4 carriers of 0.043 SUVR/year and 0.029 SUVR/year in APOE- ϵ 3 ϵ 3 subjects. However, the 95% CIs for the slope values were largely overlapping between APOE genotype classes, and therefore, the model does not support an effect of APOE genotype on the rate of A β accumulation. Individual measures of [^{11}C]PiB retention show mean annualized changes of 0.05 ± 0.07 and 0.03 ± 0.05 SUVR/year for APOE- ϵ 4 and APOE- ϵ 3 ϵ 3 subjects, respectively, which also were not significantly different ($p = 0.155$). Villemagne et al. (2011) report a mean rate of A β accumulation of APOE- ϵ 4 carriers (0.041 SUVR/year) that was similar to that observed in our study (0.05 SUVR/year) over a comparable follow-up period (38 months), although they observed a significantly slower rate of A β accumulation in APOE- ϵ 4 noncarriers (0.016 SUVR/year) than we observed in either APOE- ϵ 3 ϵ 3 (0.03 SUVR/year) or APOE- ϵ 2+ (0.04 SUVR/year) subject groups. It is possible that this discrepancy is explained by differences in the age distribution of subjects within APOE subgroups (our APOE- ϵ 3 ϵ 3 subjects were ≥ 5 years older than all diagnostic groups reported by Villemagne et al., 2011), or possibly by small sample size effects when one considers that positive SUVR changes are driven by the fraction of subjects who are PiB-positive. Nevertheless, these data suggest that, once initiated, the process of A β accumulation proceeds at a fixed rate independent of APOE genotype, that is, APOE genotype appears to affect the seeding of A β deposition more than the propagation. Furthermore, the data suggest that the increased risk of AD conferred by APOE- ϵ 4 is likely attributable to an earlier age of onset of amyloid pathology.

Finally, consistent with previous observations (Jansen et al., 2015; Morris et al., 2010), our data show APOE- ϵ 2+ subjects to have a lower rate of PiB positivity and lower baseline [^{11}C]PiB retention than APOE- ϵ 3 ϵ 3 or APOE- ϵ 4+ subjects (Table 1), and a lower rate of incident A β positivity (12.5%) than other APOE classes (33.3%). The A β trajectory models in APOE- ϵ 2+ subjects show a modestly delayed age of onset of A β positivity compared with APOE- ϵ 3 ϵ 3 subjects (82.0 years vs 77.9 years). However, longitudinal [^{11}C]PiB image data in APOE- ϵ 2+ subjects were relatively sparse compared with other genotype classes (Fig. 2), particularly so above the [^{11}C]PiB positivity threshold. As such, our trajectory model in APOE- ϵ 2+ subjects should be interpreted cautiously. However, our findings are consistent with earlier reports that describe uniformly low [^{11}C]PiB retention in APOE- ϵ 2+ subjects (Fig. 2) and a delayed age of onset of A β positivity (Jansen et al., 2015; Morris et al., 2010).

In conclusion, the present work provides further support that APOE genotype is a key modulator of amyloidogenic processes. In our study, APOE- ϵ 4 positivity was associated with increased A β load and an earlier age of onset of A β positivity compared with other APOE genotype classes, but a similar rate of amyloid accumulation. Our data also suggest a potential protective effect of APOE- ϵ 2 positivity, although the effect is likely more modest than the deleterious effects associated with APOE- ϵ 4 positivity. It is important to note that, while we and others have gathered evidence to show that APOE is an important modulator of amyloidogenesis, our data also suggest that there are likely other important factors that influence A β deposition. The variability in the age of onset of A β positivity within APOE- ϵ 4 subjects and also the lack of detectable A β deposits in some APOE- ϵ 4 positive subjects of advanced age are examples that support a more complex relationship between APOE and A β .

Disclosure statement

CAM and WEK: GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this article. WEK and CAM are coinventors of PiB and, as such, have a financial interest in this license agreement. GE Healthcare provided no financial support for this study and had no role in the design or interpretation of results or preparation of this article. All other authors have no conflicts of interest with this work and had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

CRedit authorship contribution statement

Brian J. Lopresti: Conceptualization, Data curation, Formal analysis, Methodology, Supervision, Writing - original draft, Writing - review & editing. **Elizabeth M. Campbell:** Data curation, Formal analysis, Visualization. **Zheming Yu:** Data curation, Formal analysis, Methodology, Visualization. **Stewart J. Anderson:** Methodology, Software. **Ann D. Cohen:** Investigation, Project administration, Writing - review & editing. **Davneet S. Minhas:** Methodology, Software. **Beth E. Snitz:** Investigation, Writing - review & editing. **Sarah K. Royse:** Data curation, Formal analysis. **Carl R. Becker:** Formal analysis. **Howard J. Aizenstein:** Funding acquisition, Investigation, Project administration, Resources, Writing - review & editing. **Chester A. Mathis:** Funding acquisition, Resources, Writing - review & editing. **Oscar L. Lopez:** Funding acquisition, Investigation, Project administration, Resources, Writing - review & editing. **William E. Klunk:** Funding acquisition, Investigation, Project administration, Resources, Writing - review & editing. **Dana L. Tudorascu:** Conceptualization, Formal analysis, Methodology, Resources, Supervision, Writing - original draft, Writing - review & editing.

Acknowledgements

This work was supported by grants from the National Institute on Aging: AG025204, AG005133, and AG025516.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.neurobiolaging.2020.05.012>.

References

- Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J.C., Mathis, C.A., Tsopelas, N.D., Ziolk, S.K., James, J.A., Snitz, B.E., Houck, P.R., Bi, W., Cohen, A.D., Lopresti, B.J., DeKosky, S.T., Halligan, E.M., Klunk, W.E., 2008. Frequent amyloid deposition without significant cognitive impairment among the elderly. *Arch. Neurol.* 65, 1509–1517.
- Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, M.C., Thies, B., Phelps, C.H., 2011. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 7, 270–279.
- Bekris, L.M., Galloway, N.M., Millard, S., Lockhart, D., Li, G., Galasko, D.R., Farlow, M.R., Clark, C.M., Quinn, J.F., Kaye, J.A., Schellenberg, G.D., Leverenz, J.B., Seubert, P., Tsuang, D.W., Peskind, E.R., Yu, C.E., 2011. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. *Neurobiol. Aging* 32, 556.e13–556.e23.
- Bertram, L., McQueen, M.B., Mullin, K., Blacker, D., Tanzi, R.E., 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nat. Genet.* 39, 17–23.
- Bilgel, M., An, Y., Zhou, Y., Wong, D.F., Prince, J.L., Ferrucci, L., Resnick, S.M., 2016. Individual estimates of age at detectable amyloid onset for risk factor assessment. *Alzheimers Dement.* 12, 373–379.
- Bird, T.D., 2008. Genetic aspects of Alzheimer disease. *Genet. Med.* 10, 231–239.
- Blacker, D., Haines, J.L., Rodes, L., Terwedow, H., Go, R.C., Harrell, L.E., Perry, R.T., Bassett, S.S., Chase, G., Meyers, D., Albert, M.S., Tanzi, R., 1997. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. *Neurology* 48, 139–147.
- Bonham, L.W., Geier, E.G., Fan, C.C., Leong, J.K., Besser, L., Kukull, W.A., Kornak, J., Andreassen, O.A., Schellenberg, G.D., Rosen, H.J., Dillon, W.P., Hess, C.P., Miller, B.L., Dale, A.M., Desikan, R.S., Yokoyama, J.S., 2016. Age-dependent effects of APOE epsilon4 in preclinical Alzheimer's disease. *Ann. Clin. Transl. Neurol.* 3, 668–677.
- Borenstein, A.R., Copenhaver, C.I., Mortimer, J.A., 2006. Early-life risk factors for Alzheimer disease. *Alzheimer Dis. Assoc. Disord.* 20, 63–72.
- Butters, M.A., Klunk, W.E., Mathis, C.A., Price, J.C., Ziolk, S.K., Hoge, J.A., Tsopelas, N.D., Lopresti, B.J., Reynolds 3rd, C.F., DeKosky, S.T., Meltzer, C.C., 2008. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh compound-B. *Alzheimer Dis. Assoc. Disord.* 22, 261–268.
- Cohen, A.D., Mowrey, W., Weissfeld, L.A., Aizenstein, H.J., McDade, E., Mountz, J.M., Nebes, R.D., Saxton, J.A., Snitz, B., Dekosky, S., Williamson, J., Lopez, O.L., Price, J.C., Mathis, C.A., Klunk, W.E., 2013. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. *Neuroimage* 71, 207–215.
- Cohen, A.D., Price, J.C., Weissfeld, L.A., James, J., Rosario, B.L., Bi, W., Nebes, R.D., Saxton, J.A., Snitz, B.E., Aizenstein, H.A., Wolk, D.A., Dekosky, S.T., Mathis, C.A., Klunk, W.E., 2009. Basal cerebral metabolism may modulate the cognitive effects of Aβeta in mild cognitive impairment: an example of brain reserve. *J. Neurosci.* 29, 14770–14778.
- Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., Pericak-Vance, M.A., 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261, 921–923.
- Durmaz, A., Kumral, E., Durmaz, B., Onay, H., Aslan, G.I., Ozkinay, F., Pehlivan, S., Orman, M., Cogulu, O., 2019. Genetic factors associated with the predisposition to late onset Alzheimer's disease. *Gene* 707, 212–215.
- Eichner, J.E., Kuller, L.H., Ferrell, R.E., Meilahn, E.N., Kamboh, M.I., 1990. Phenotypic effects of apolipoprotein structural variation on lipid profiles. III. Contribution of apolipoprotein E phenotype to prediction of total cholesterol, apolipoprotein B, and low density lipoprotein cholesterol in the healthy women study. *Arteriosclerosis* 10, 379–385.
- Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, R.H., Pericak-Vance, M.A., Risch, N., van Duijn, C.M., 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA* 278, 1349–1356.
- Fleisher, A.S., Chen, K., Liu, X., Ayutyanont, N., Roontiva, A., Thiyyagura, P., Protas, H., Joshi, A.D., Sabbagh, M., Sadowsky, C.H., Sperling, R.A., Clark, C.M., Mintun, M.A., Pontecorvo, M.J., Coleman, R.E., Doraiswamy, P.M., Johnson, K.A., Carpenter, A.P., Skovronsky, D.M., Reiman, E.M., 2013. Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. *Neurobiol. Aging* 34, 1–12.
- Gatz, M., Reynolds, C.A., Fratiglioni, L., Johansson, B., Mortimer, J.A., Berg, S., Fiske, A., Pedersen, N.L., 2006. Role of genes and environments for explaining Alzheimer disease. *Arch. Gen. Psychiatry* 63, 168–174.
- Grimmer, T., Tholen, S., Yousefi, B.H., Alexopoulos, P., Forschler, A., Forstl, H., Henriksen, G., Klunk, W.E., Mathis, C.A., Perneczky, R., Sorg, C., Kurz, A., Drzezga, A., 2010. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. *Biol. Psychiatry* 68, 879–884.
- Jack Jr., C.R., Holtzman, D.M., 2013. Biomarker modeling of Alzheimer's disease. *Neuron* 80, 1347–1358.
- Jack Jr., C.R., Wiste, H.J., Lesnick, T.G., Weigand, S.D., Knopman, D.S., Vemuri, P., Pankratz, V.S., Senjem, M.L., Gunter, J.L., Mielke, M.M., Lowe, V.J., Boeve, B.F., Petersen, R.C., 2013. Brain beta-amyloid load approaches a plateau. *Neurology* 80, 890–896.
- Jack Jr., C.R., Wiste, H.J., Weigand, S.D., Knopman, D.S., Vemuri, P., Mielke, M.M., Lowe, V., Senjem, M.L., Gunter, J.L., Machulda, M.M., Gregg, B.E., Pankratz, V.S., Rocca, W.A., Petersen, R.C., 2015. Age, sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the Adult life span. *JAMA Neurol.* 72, 511–519.
- Jansen, W.J., Ossenkoppele, R., Knol, D.L., Tijms, B.M., Scheltens, P., Verhey, F.R., Visser, P.J., 2019. Amyloid Biomarker Study Group, Aalten, P., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I.S., Arnold, S.E., Baldeiras, I., Barthel, H., van Berckel, B.N., Bibeau, K., Blennow, K., Brooks, D.J., van Buchem, M.A., Camus, V., Cavedo, E., Chen, K., Chetelat, G., Cohen, A.D., Drzezga, A., Engelborghs, S., Fagan, A.M., Fladby, T., Fleisher, A.S., van der Flier, W.M., Ford, L., Forster, S., Fortea, J., Fosskett, N., Frederiksen, K.S., Freund-Levi, Y., Frisoni, G.B., Froelich, L., Gabryelewicz, T., Gill, K.D., Gkatzima, O., Gomez-Tortosa, E., Gordon, M.F., Grimmer, T., Hampel, H., Hausner, L., Hellwig, S., Herukka, S.K., Hildebrandt, H., Ishihara, L., Ivanoiu, A., Jagust, W.J., Johannsen, P., Kandimalla, R., Kapaki, E., Klimkiewicz-Mrowiec, A., Klunk, W.E., Kohler, S., Koglin, N., Kornhuber, J., Kramberger, M.G., Van Laere, K., Landau, S.M., Lee, D.Y., de Leon, M., Lisetti, V., Lleo, A., Madsen, K., Maier, W., Marcussen, J., Mattsson, N., de Mendonca, A., Meulenbroek, O., Meyer, P.T., Mintun, M.A., Mok, V., Molinuevo, J.L., Mollergard, H.M., Morris, J.C., Mroczko, B., Van der Mussele, S., Na, D.L., Newberg, A., Nordberg, A., Nordlund, A., Novak, G.P., Paraskevas, G.P., Parnetti, L., Perera, G., Peters, O., Popp, J., Prabhakar, S., Rabinovici, G.D., Ramakers, I.H., Rami, L., Resende de Oliveira, C., Rinne, J.O., Rodrigue, K.M.,

- Rodriguez-Rodriguez, E., Roe, C.M., Rot, U., Rowe, C.C., Ruther, E., Sabri, O., Sanchez-Juan, P., Santana, I., Sarazin, M., Schroder, J., Schutte, C., Seo, S.W., Soetewey, F., Soininen, H., Spuru, L., Struyfs, H., Teunissen, C.E., Tsolaki, M., Vandenbergh, R., Verbeek, M.M., Villemagne, V.L., Vos, S.J., van Waalwijk van Doorn, L.J., Waldemar, G., Wallin, A., Wallin, A.K., Wiltfang, J., Wolk, D.A., Zboch, M., Zetterberg, H., 2015. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA* 313, 1924–1938.
- Kamboh, M.I., Aston, C.E., Hamman, R.F., 1995. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. *Atherosclerosis* 112, 145–159.
- Kenward, M.G., Roger, J.H., 1997. Small sample inference for fixed effects from restricted maximum likelihood. *Biometrics* 53, 983–997.
- Kim, Y.J., Seo, S.W., Park, S.B., Yang, J.J., Lee, J.S., Lee, J., Jang, Y.K., Kim, S.T., Lee, K.H., Lee, J.M., Lee, J.H., Kim, J.S., Na, D.L., Kim, H.J., 2017. Protective effects of APOE $\epsilon 2$ against disease progression in subcortical vascular mild cognitive impairment patients: a three-year longitudinal study. *Sci. Rep.* 7, 1910.
- Lim, Y.Y., Mormino, E.C., Alzheimer's Disease Neuroimaging Initiative, 2017. APOE genotype and early beta-amyloid accumulation in older adults without dementia. *Neurology* 89, 1028–1034.
- Lopez, O.L., Becker, J.T., Chang, Y., Klunk, W.E., Mathis, C., Price, J., Aizenstein, H.J., Snitz, B., Cohen, A.D., Dekosky, S.T., Ikonovic, M., Kamboh, M.I., Kuller, L.H., 2018. Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. *Neurology* 90, e1920–e1928.
- Mathis, C.A., Kuller, L.H., Klunk, W.E., Snitz, B.E., Price, J.C., Weissfeld, L.A., Rosario, B.L., Lopresti, B.J., Saxton, J.A., Aizenstein, H.J., McDade, E.M., Kamboh, M.I., DeKosky, S.T., Lopez, O.L., 2013. In vivo assessment of amyloid-beta deposition in nondemented very elderly subjects. *Ann. Neurol.* 73, 751–761.
- Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Yarasheski, K.E., Bateman, R.J., 2010. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science* 330, 1774.
- McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack Jr., C.R., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S., Phelps, C.H., 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 7, 263–269.
- McNamee, R.L., Yee, S.H., Price, J.C., Klunk, W.E., Rosario, B., Weissfeld, L., Ziolk, S., Berginc, M., Lopresti, B., Dekosky, S., Mathis, C.A., 2009. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. *J. Nucl. Med.* 50, 348–355.
- Mecca, A.P., Barcelos, N.M., Wang, S., Bruck, A., Nabulsi, N., Planeta-Wilson, B., Nadelmann, J., Benincasa, A.L., Ropchan, J., Huang, Y., Gelernter, J., Van Ness, P.H., Carson, R.E., van Dyck, C.H., 2018. Cortical beta-amyloid burden, gray matter, and memory in adults at varying APOE epsilon4 risk for Alzheimer's disease. *Neurobiol. Aging* 61, 207–214.
- Meltzer, C.C., Leal, J.P., Mayberg, H.S., Wagner Jr., H.N., Frost, J.J., 1990. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. *J. Comput. Assist. Tomogr.* 14, 561–570.
- Mishra, S., Blazey, T.M., Holtzman, D.M., Cruchaga, C., Su, Y., Morris, J.C., Benzinger, T.L.S., Gordon, B.A., 2018. Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE epsilon4 genotype. *Brain* 141, 1828–1839.
- Morris, C.M., Benjamin, R., Leake, A., McArthur, F.K., Candy, J.M., Ince, P.G., Torvik, A., Bjertness, E., Edwardson, J.A., 1995. Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians. *Neurosci. Lett.* 201, 45–47.
- Morris, J.C., Roe, C.M., Xiong, C., Fagan, A.M., Goate, A.M., Holtzman, D.M., Mintun, M.A., 2010. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann. Neurol.* 67, 122–131.
- Nadkarni, N.K., Tudorascu, D., Campbell, E., Snitz, B.E., Cohen, A.D., Halligan, E., Mathis, C.A., Aizenstein, H.J., Klunk, W.E., 2019. Association between amyloid-beta, small-vessel disease, and Neurodegeneration biomarker positivity, and progression to mild cognitive impairment in cognitively normal individuals. *J. Gerontol. A Biol. Sci. Med. Sci.* 74, 1753–1760.
- Nagy, Z., Esiri, J.M., Jobst, K.A., Johnston, C., Litchfield, S., Sim, E., Smith, A.D., 1995. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. *Neuroscience* 69, 757–761.
- Price, J.C., Klunk, W.E., Lopresti, B.J., Lu, X., Hoge, J.A., Ziolk, S.K., Holt, D.P., Meltzer, C.C., Dekosky, S.T., Mathis, C.A., 2005. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. *J. Cereb. Blood Flow Metab.* 25, 1528–1547.
- Qian, J., Wolters, F.J., Beiser, A., Haan, M., Ikram, M.A., Karlawish, J., Langbaum, J.B., Neuhaus, J.M., Reiman, E.M., Roberts, J.S., Seshadri, S., Tariot, P.N., Woods, B.M., Betensky, R.A., Blacker, D., 2017. APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. *PLoS Med.* 14, e1002254.
- Rall Jr., S.C., Weisgraber, K.H., Mahley, R.W., 1982. Human apolipoprotein E. The complete amino acid sequence. *J. Biol. Chem.* 257, 4171–4178.
- Resnick, S.M., Bilgel, M., Moghekar, A., An, Y., Cai, Q., Wang, M.C., Thambisetty, M., Prince, J.L., Zhou, Y., Soldan, A., Wong, D.F., O'Brien, R.J., Ferrucci, L., Albert, M.S., 2015. Changes in Abeta biomarkers and associations with APOE genotype in 2 longitudinal cohorts. *Neurobiol. Aging* 36, 2333–2339.
- Roda, A.R., Montoliu-Gaya, L., Villegas, S., 2019. The role of apolipoprotein E isoforms in Alzheimer's disease. *J. Alzheimers Dis.* 68, 459–471.
- Rosario, B.L., Weissfeld, L.A., Laymon, C.M., Mathis, C.A., Klunk, W.E., Berginc, M.D., James, J.A., Hoge, J.A., Price, J.C., 2011. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. *Neuroimage* 55, 933–941.
- Sando, S.B., Melquist, S., Cannon, A., Hutton, M.L., Sletvold, O., Saltvedt, I., White, L.R., Lydersen, S., Aasly, J.O., 2008. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. *BMC Neurol.* 8, 9.
- Saunders, A.M., Strittmatter, W.J., Schmechel, D., George-Hyslop, P.H., Pericak-Vance, M.A., Joo, S.H., Rosi, B.L., Gusella, J.F., Crapper-MacLachlan, D.R., Alberts, M.J., Hulette, C., Crain, B., Goldgaber, D., Roses, A.D., 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology* 43, 1467–1472.
- Schmechel, D.E., Saunders, A.M., Strittmatter, W.J., Crain, B.J., Hulette, C.M., Joo, S.H., Pericak-Vance, M.A., Goldgaber, D., Roses, A.D., 1993. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. *Proc. Natl. Acad. Sci. U. S. A.* 90, 9649–9653.
- Singh, P.P., Singh, M., Mastana, S.S., 2006. APOE distribution in world populations with new data from India and the UK. *Ann. Hum. Biol.* 33, 279–308.
- Snitz, B.E., Lopez, O.L., McDade, E., Becker, J.T., Cohen, A.D., Price, J.C., Mathis, C.A., Klunk, W.E., 2015. Amyloid-beta imaging in older adults presenting to a memory clinic with subjective cognitive decline: a Pilot study. *J. Alzheimers Dis.* 48 (Suppl 1), S151–S159.
- Tang, M.X., Maestre, G., Tsai, W.Y., Liu, X.H., Feng, L., Chung, W.Y., Chun, M., Schofield, P., Stern, Y., Tycko, B., Mayeux, R., 1996. Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. *Am. J. Hum. Genet.* 58, 574–584.
- Tudorascu, D.L., Anderson, S.J., Minhas, D.S., Yu, Z., Comer, D., Lao, P., Hartley, S., Laymon, C.M., Snitz, B.E., Lopresti, B.J., Johnson, S., Price, J.C., Mathis, C.A., Aizenstein, H.J., Klunk, W.E., Handen, B.L., Christian, B.T., Cohen, A.D., 2019. Comparison of longitudinal Abeta in nondemented elderly and down syndrome. *Neurobiol. Aging* 73, 171–176.
- van der Flier, W.M., Pijnenburg, Y.A., Schoonenboom, S.N., Dik, M.G., Blankenstein, M.A., Scheltens, P., 2008. Distribution of APOE genotypes in a memory clinic cohort. *Dement. Geriatr. Cogn. Disord.* 25, 433–438.
- Villemagne, V.L., Pike, K.E., Chetelat, G., Ellis, K.A., Mulligan, R.S., Bourgeat, P., Ackermann, U., Jones, G., Szeke, C., Salvado, O., Martins, R., O'Keefe, G., Mathis, C.A., Klunk, W.E., Ames, D., Masters, C.L., Rowe, C.C., 2011. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. *Ann. Neurol.* 69, 181–192.
- Villeneuve, S., Rabinovici, G.D., Cohn-Sheehy, B.I., Madison, C., Ayakta, N., Ghosh, P.M., La Joie, R., Arthur-Bentil, S.K., Vogel, J.W., Marks, S.M., Lehmann, M., Rosen, H.J., Reed, B., Olichney, J., Boxer, A.L., Miller, B.L., Borys, E., Jin, L.W., Huang, E.J., Grinberg, L.T., DeCarli, C., Seeley, W.W., Jagust, W., 2015. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. *Brain* 138 (Pt 7), 2020–2033.
- Wilson, R.S., Bienias, J.L., Berry-Kravis, E., Evans, D.A., Bennett, D.A., 2002. The apolipoprotein E epsilon 2 allele and decline in episodic memory. *J. Neurol. Neurosurg. Psychiatry* 73, 672–677.
- Wirth, M., Villeneuve, S., La Joie, R., Marks, S.M., Jagust, W.J., 2014. Gene-environment interactions: lifetime cognitive activity, APOE genotype, and beta-amyloid burden. *J. Neurosci.* 34, 8612–8617.
- Wolk, D.A., Price, J.C., Madeira, C., Saxton, J.A., Snitz, B.E., Lopez, O.L., Mathis, C.A., Klunk, W.E., DeKosky, S.T., 2012. Amyloid imaging in dementias with atypical presentation. *Alzheimers Dement.* 8, 389–398.
- Yan, Q., Nho, K., Del-Aguila, J.L., Wang, X., Risacher, S.L., Fan, K.H., Snitz, B.E., Aizenstein, H.J., Mathis, C.A., Lopez, O.L., Demirci, F.Y., Feingold, E., Klunk, W.E., Saykin, A.J., Alzheimer's Disease Neuroimaging Initiative (ADNI), Cruchaga, C., Kamboh, M.I., 2018. Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. *Mol. Psychiatry*.
- Zwan, M.D., Villemagne, V.L., Dore, V., Buckley, R., Bourgeat, P., Veljanoski, R., Salvado, O., Williams, R., Margison, L., Rembach, A., Macaulay, S.L., Martins, R., Ames, D., van der Flier, W.M., Ellis, K.A., Scheltens, P., Masters, C.L., Rowe, C.C., 2016. Subjective memory complaints in APOE epsilon4 carriers are associated with high amyloid-beta burden. *J. Alzheimers Dis.* 49, 1115–1122.